AN2 Therapeutics, Inc. (Nasdaq: ANTX) has announced a collaboration with the Drugs for Neglected Diseases initiative (DNDi) to advance the clinical development of AN2-502998, an oral drug candidate for the treatment of chronic Chagas disease. This partnership aims to leverage DNDi's extensive expertise in Chagas disease clinical trials, enhancing resource optimization and scientific execution. The initiative is part of DNDi's broader pipeline focused on novel treatments for Chagas disease. The collaboration will also include biomarker research and implementation studies to ensure effective diagnostics and treatments reach the patients in need. Results of the ongoing development have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。